Cougar Biotechnology jumps on narrower-than-expected Q4 loss
Shares of Cougar Biotechnology, Inc. (Nasdaq:CGRB) spiked in pre-market trading after the developer of clinical stage cancer drug candidates this morning reported a narrower-than-expected net loss in the fourth-quarter and lessened its loss from a year ago. Shares jumped 19%, or $3.96 to $24.67 in pre-market trading.
For detailed price information and recent news stories about Cougar Biotechnology, click CGRB.
